This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Salay, G.
Right arrow Articles by Rodrigues, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salay, G.
Right arrow Articles by Rodrigues, M. M.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, September 2007, p. 1173-1181, Vol. 14, No. 9
1071-412X/07/$08.00+0     doi:10.1128/CVI.00060-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Testing of Four Leishmania Vaccine Candidates in a Mouse Model of Infection with Leishmania (Viannia) braziliensis, the Main Causative Agent of Cutaneous Leishmaniasis in the New World{triangledown}

G. Salay,1,2 M. L. Dorta,1,3 N. M. Santos,1,2 R. A. Mortara,2 C. Brodskyn,4,5 C. I. Oliveira,4 C. L. Barbiéri,2 and M. M. Rodrigues1,2*

Centro Interdisciplinar de Terapia Gênica, Universidade Federal de São Paulo-Escola Paulista de Medicina, Rua Mirassol, 207, São Paulo, SP 04044-010, Brazil,1 Disciplina de Parasitologia-Departamento de Microbiologia, Imunologiae Parasitologia, Universidade Federal de São Paulo-Escola Paulista de Medicina, Rua Botucatu, 862, 60 Andar, São Paulo, SP 04023-062, Brazil,2 Disciplina de Imunologia-Departamento de Microbiologia Imunonologia e Parasitologia, Universidade Federal de Goiânia, Goiânia, Brazil,3 Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Rua Waldemar Falcão, 121, Salvador, BA 40295-001, Brazil,4 Departamento de Biointeração, Instituto de Ciências da Saúde, Universidade Federal da Bahia, Av. Reitor Miguel Calmon, S/N, Salvador, BA 40110-160, Brazil5

Received 1 February 2007/ Returned for modification 2 April 2007/ Accepted 11 June 2007

We evaluated whether four recombinant antigens previously used for vaccination against experimental infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii) thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L. (V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L. (V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishmaniasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although negative, we consider our results important since they suggest that studies aimed at the development of an effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World, should be redirected toward distinct antigens or different vaccination strategies.

* Corresponding author. Mailing address: CINTERGEN-Centro Interdisciplinar de Terapia Gênica, UNIFESP-EPM, Rua Mirassol, 207, São Paulo, SP 04044-010, Brazil. Phone: 55-11-5084-8807. Fax: 55-11-5574-5071. E-mail: mrodrigues{at}ecb.epm.br

{triangledown} Published ahead of print on 11 July 2007.

Clinical and Vaccine Immunology, September 2007, p. 1173-1181, Vol. 14, No. 9
1071-412X/07/$08.00+0     doi:10.1128/CVI.00060-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»